ImmVirX Reports Encouraging Phase 1b Clinical Data for IVX037 and Highlights Broad Preclinical Activity of IVX055 at AACR 2026
IVX037 data demonstrate favourable safety profile, abscopal effects and enhanced activity in KRAS/BRAF-mutant tumours; IVX055 shows potent anti-tumour activity across multiple solid tumour types Melbourne, Australia 21 April 2026 – ImmVirX Pty Limited, a life sciences company developing next-generation, receptor-targeted oncolytic RNA immunotherapies, today announced the presentation of new clinical and translational data for its […]
ImmVirX Poster Presentations on Preclinical and Clinical Programs at AACR Annual Meeting, San Diego
Melbourne, Australia 18 March 2026 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April […]
ImmVirX and BeOne Medicines Enter Clinical Collaboration to Evaluate IVX055 in Combination with tislelizumab
Phase 1 study to investigate IVX055 with tislelizumab in difficult-to-treat cancers Key Highlights ImmVirX’s receptor-targeted oncolytic virus IVX055 to be evaluated in combination with tislelizumab Phase 1 clinical trial planned to commence in second half 2026 in Australia IVX055 to become ImmVirX’s second clinical-stage asset, expanding its oncolytic immunotherapy pipeline Melbourne, Australia – 3 February […]
ImmVirX receives $6.27 million R&D Tax Incentive Cash Offset from ATO
Melbourne, Australia 13 January 2026 – ImmVirX Pty Limited (“ImmVirX”), a clinical-stage life sciences company developing next-generation, receptor-targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $6,274,594 Research and Development (R&D) Tax Incentive refund from the Australian Taxation Office (ATO). This amount […]
ImmVirX Presents Promising Clinical Data on IVX037 at ESMO 2025, Highlighting Activity in MSS-CRC and Ovarian Cancer
Intratumoural IVX037 showed encouraging biological and clinical activity in microsatellite stable colorectal cancer (MSS-CRC), both as a monotherapy and in combination with the PD-1 inhibitor sintilimab, particularly in KRAS/BRAF-mutant tumours. Disease control was observed in several MSS-CRC patients with liver metastases, especially those harbouring KRAS/BRAF mutations. IVX037 treatment demonstrated abscopal effects, with responses in liver, […]
ImmVirX reports on operations for FY25
Melbourne, Australia 18 September 2025 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generation of receptor-targeted immunotherapies for patients confronted with common yet formidable cancers, is pleased to provide a summary of its operations for the financial year ended 30 June 2025. Over the past year, ImmVirX has made significant […]
ImmVirX selected for Clinical E-Poster Presentation at ESMO Congress, Berlin
Melbourne, Australia 25 July 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, will present an e-poster at the European Society for Medical Oncology (ESMO) Congress taking place in Berlin, Germany […]
ImmVirX presents clinical and preclinical updates at American Association for Cancer Research (AACR) Annual Meeting
Phase 1a monotherapy trial complete Well tolerated with no dose limiting toxicities Confirmed pathologic complete response in a target lesion in a colorectal cancer patient with no new sites of metastatic lesions approaching two years since commencing treatment Signs of monotherapy activity in 2 of 9 late-stage cancer patients Induction of cell signalling proteins (cytokines/chemokines), […]
ImmVirX and Innovent Expand Collaboration to Investigate IVX037 with TYVYT® in Liver Cancer
Melbourne, Australia 28 April 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, is pleased to announce it has expanded its clinical trial collaboration and supply agreement with Innovent Biologics, Inc. […]
ImmVirX Poster Presentations on Preclinical and Clinical Programs at AACR Annual Meeting, Chicago
Melbourne, Australia 27 March 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April […]
